medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2015, Number 1

Next >>

Arch Neurocien 2015; 20 (1)

Olanzapine and fluoxetine combined as therapy for treatment-resistant depression: a systematic review

Tamayo JM, Pica-Ruiz Y, Ruiz I

Language: English
References: 52
Page: 3-19
PDF size: 192.14 Kb.


ABSTRACT

Objective: we conducted a systematic review to evaluate the evidence for the efficacy and safety of olanzapinefluoxetine combined (OFC) in patients with treatment-resistant depression (TRD). Material and methods: MEDLINE, EMBASE, Cochrane Library, ClinicalTrials.gov, and LillyTrials.com were searched (28 February 2014) using terms related to TRD and OFC (no language restrictions). All prospective studies of OFC treatment of TRD were included. Results: we included 16 studies (5 meta-analyses, 3 pooled analyses, 7 randomized controlled trials [RCTs], 1 nonrandomized, open-label trial); unpublished data of open-label extensions were available for 4 RCTs. The definition of TRD varied; most studies defined TRD as response failure after 2 antidepressant trials of≥4 weeks. All RCTs compared OFC with fluoxetine. Treatment duration was 4 12 weeks in RCTs, and 8 76 weeks in open-label studies. Depressive symptoms improved with OFC treatment in all studies; improvement was generally greater and occurred earlier than with fluoxetine and was sustained during longer-term treatment. Response (27.5%-80%) and remission (16.9%-73.3%) rates were generally greater than with fluoxetine. Weight gain and changes in metabolic parameters were generally more common in patients treated with OFC than with fluoxetine. Other adverse events and discontinuation rates were similar to those seen with fluoxetine. Conclusions: evidence from prospective studies supports the efficacy of OFC in the treatment of TRD, which is sustained with longer-term treatment. However, there may be a greater risk of weight gain and changes in metabolic parameters. Physicians may consider OFC as treatment for TRD, provided the risks of weight gain and metabolic changes are actively managed.


REFERENCES

  1. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011;9:90. doi:10.1186/ 1741-7015-9-90.

  2. Vicente B, Kohn R, Rioseco P, Saldivia S, Levav I, Torres S. Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study. Am J Psychi 2006;163 (8):1362-70.

  3. Miret M, Ayuso-Mateos JL, Sanchez-Moreno J, Vieta E. Depressive disorders and suicide: epidemiology, risk factors, and burden. Neurosci Biobehav Rev 2013;37(10 Pt 1):2372-4.

  4. Lerner D, Henke RM. What does research tell us about depression, job performance, and work productivity? J Occup Environ Med 2008;50(4):401-10.

  5. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(Suppl 5):28-34.

  6. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med 2008;75(1):57-66.

  7. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9(6):449-59.

  8. McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 2014;156:1-7.

  9. Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One 2013;8(10):e76882. doi:10.1371/journal.pone. 0076882.

  10. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychi 2002; 63 (11): 963-71.

  11. Levav I, Kohn R, Montoya I, Palacio C, Rozic P, Solano I, et al. Training Latin American primary care physicians in the WPA module on depression: results of a multicenter trial. Psychol Med 2005;35(1):35-45.

  12. Tamayo JM, Rosales-Barrera JI, Villaseñor-Bayardo SJ, Rojas- Malpica C. Revisión de la literatura médica sobre el manejo de las depresiones resistentes/refractarias al tratamiento [Spanish]. Sal Ment 2011;34:257-66.

  13. Gaynes BN, Lux LJ, Lloyd SW, Hansen RA, Gartlehner G, Keener P, et al. Nonpharmacologic inter ventions for treatmentresistant depression in adults. AHRQ Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2011.

  14. Preston TC, Shelton RC. Treatment resistant depression: Strategies for primary care topical collection on psychiatry in primary care. Curr Psychiatr Rep 2013;15(7). doi:10.1007/ 511 920-013-0370-7.

  15. Kato M, Chang CM. Augmentation treatments with secondgeneration antipsychotics to antidepressants in treatmentresistant depression. CNS Drugs 2013;27(Suppl 1):S11- S119.

  16. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a metaanalysis. J Clin Psychiatry 2007;68(6):826-31.

  17. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Act Psychiat Scand 2008;117(4):253-9.

  18. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psych 2009; 166(9):980-91.

  19. Komossa K, Depping Anna M, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database of Systematic Reviews 2010(12). doi:10.1002/14651858.CD008121. pub2.

  20. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013;10(3): doi:10.1371/journal.pmed.1001403.

  21. Feng HM, Meifang C, Yunhai T. Efficacy of olanzapine and fluoxetine combination therapy in treatment-resistant depression. Zheijang Pract Med 2008;13:117-8.

  22. Li HZ, Zhang YL, Zhang YL, Li MZ. Double-blind study of fluoxetine augmented with olanzapine in the treatment of treatment-resistant depression. Shandong Arch Psych 2006;19(2):85-6.

  23. Wang B, Hu JM, Li BH, Zhang XM. A clinical comparative study of olanzapine augmented with fluoxetine on the refractory depression. Shandong Arch Psych 2006;19(2):87-9.

  24. Wang XH, Guo XD, Liu M. Effectiveness and safety of olanzapine combined with fluoxetine for refractory depression: A systematic review. [Chinese]. Chin J Evid Based Med 2010;10(9):1102-9.

  25. Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov A, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2011;44(4):57-90.

  26. Kennedy SH. A review of antidepressant therapy in primary care: current practices and future directions. Prim Care Companion CNS Disord 2013;15(2). doi: 10.4088/ PCC.12r01420.

  27. Pridmore S, Turnier-Shea Y. Medication options in the treatment of treatment-resistant depression. Aust N Z J Psychiat 2004;38(4):219-25.

  28. Santos MA, Hara C, Stumpf BLP, Rocha FL. Treatment-resistant depression: Review of pharmacologic antidepressant strategies. [Portuguese] Depressao resistente a tratamento: Uma revisao das estrategias farmacologicas de potencializacao de antidepressivos. J Brasil Psiq 2006;55 (3):232-42.

  29. Stimpson N, Agrawal N, Lewis G. Randomised controlled trials investigating pharmacological and psychological inter ventions for treatment-refractor y depression. Br J Psychiatry 2002;181:284-94.

  30. Wright BM, Eiland EH, Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based suppor t from the medical literature. Pharmacotherapy 2013;33(3):344-59.

  31. Eli Lilly Clinical Trial Results. Study of olanzapine in treatment resistant major depressive disorder without psychotic features (Lilly registry ID #1034). 2006. Available at http:// www.lillytrials.com/results/Symbyax.pdf. Accessed 3 March 2014.

  32. Eli Lilly Clinical Trial Results. The combination of olanzapine and fluoxetine in treatment resistant depression without psychotic features (Lilly registry ID #3079). 2006. Available at http://www.lillytrials.com/results/Symbyax.pdf. Accessed 3 March 2014.

  33. Eli Lilly Clinical Trial Results. Olanzapine plus fluoxetine combination therapy in treatment-resistant depression: A dose ranging study (Lilly registry ID #3641). 2006. Available at http://www.lillytrials.com/results/Symbyax.pdf. Accessed 3 March 2014.

  34. Eli Lilly Clinical Trial Results. The study of olanzapine plus fluoxetine in combination for treatment-resistant depression without psychotic features (Lilly registry ID #6272). 2006. Available at http://www.lillytrials.com/results/Symbyax.pdf. Accessed 3 March 2014.

  35. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158(1):131-4.

  36. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psych 2005;66(10):1289- 97.

  37. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23(6):364-72.

  38. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68(2):224-36.

  39. Corya SA, Andersen SW, Detke HC, Kelly LS, Van Campen LE, Sanger TM, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: A 76-week open-label study. J Clin Psychiatry 2003;64(11):1349-56.

  40. Degenhardt EK, Jamal HH, Tormey S, Case M. Early weight gain as a predictor of substantial weight gain with olanzapine/ fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. J Clin Psychopharmacol 2011;31(3):337-40.

  41. Edwards SJ, Hamilton V, Nherera L, Trevor N. Lithium or an atypical antipsychotic drug in the management of treatmentresistant depression: a systematic review and economic evaluation. Health Technol Assess 2013;17(54):1-190.

  42. Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011;72(8):1063-71.

  43. Tohen M, Case M, Trivedi MH, Thase ME, Burke SJ, Durell TM. Olanzapine/fluoxetine combination in patients with treatmentresistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010;71(4):451-62.

  44. Trivedi MH, Thase ME, Osuntokun O, Henley DB, Case M, Watson SB, et al. An integrated analysis of olanzapine/ fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009;70(3):387-96.

  45. Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology 2014. doi:10.1038/npp.2014. 101.

  46. Cordes J, Thunker J, Regenbrecht G, Zielasek J, Correll CU, Schmidt-Kraepelin C, et al. Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. World J Biol Psychiatry 2014;15(3):229-41.

  47. Holtzheimer PE. Advances in the management of treatmentresistant depression. Focus J Lifelong Learning Psychiatry 2010;VIII(4):488-500.

  48. Bobo WV, Shelton RC. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: Review of efficacy, safety, and study design issues. Neuropsychiatr Dis Treat 2009;5(1):369-83.

  49. Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, et al. European Group for the Study of Resistant Depression (GSRD)-where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol 2012;22(7):453-68.

  50. National Institute for Health and Clinical Excellence. Depression in adults: the treatment and management of depression in adults. NICE clinical guideline 90 [Internet]. 2009 Accessed: August 3, 2014. Available from: www.nice.org.uk/CG90.

  51. Mitchell J, Trangle M, Degnan B, Gabert T, Haight B, Kessler D, et al. Institute for Clinical Systems Improvement. Adult depression in primary care. 2013 accessed: August 4, 2014. Available from: https://www.icsi.org/_asset/fnhdm3/Depr- Interactive0512b.pdf.

  52. Tamayo JM, Rosales-Barrera JI, Villaseñor-Bayardo SJ, Rojas- Malpica C. Definiciónimpacto de las depresiones resistentes/refractarias al tratamiento [Spanish]. Sal Ment 2011;34:247-55.




2020     |     www.medigraphic.com